Affimed Enters into Collaboration with Merck to Evaluate AFM13 in Combination with KEYTRUDA® (pembrolizumab) for Patients with Hodgkin Lymphoma January 25, 2016
Affimed Appoints Dr. Joerg Windisch as Chief Operating Officer and Adds Dr. Bernhard Ehmer to Supervisory Board January 21, 2016
Affimed to Host Hodgkin’s Lymphoma Day with Key Opinion Leaders on January 26th in New York City January 20, 2016
